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ABSTRACT
Background Cirrhotic patients are at considerable risk for bacterial infections, possibly through increased intes-
tinal permeability and bacterial overgrowth. Proton pump inhibitors (PPIs) may increase infection risk. We aimed
to explore the potential association between PPI use and bacterial infection risk in cirrhotic patients and potential
underlying mechanisms in complementary patient and animal models.
Materials and methods Bacterial overgrowth was determined in jejunum of 30 rats randomly allocated to
6-week PPI treatment, gastrectomy or no treatment. In 84 consecutive cirrhotic patients, bacterial infection risk
was prospectively assessed and related to PPI use. Intestinal permeability was determined by polyethylene
glycol (PEG) test in nine healthy individuals and 12 cirrhotic patients.
Results Bacterial overgrowth was much more common in jejunum of rats treated with PPI or gastrectomy
compared with nontreated rats. Twenty-four patients (29%) developed a bacterial infection during a median
follow-up of 28 months. Although PPI users tended to experience infection more often than patients without
PPI therapy, PPI use was not an independent predictor of bacterial infection (HR 1Æ2, 95% CI 0Æ5–3Æ0, P = 0Æ72),
after correction for Child-Pugh class (HR 3Æ6, 95% CI 1Æ5–8Æ7, P = 0Æ004) and age (HR 1Æ05, 95%CI 1Æ01–1Æ09,
P = 0Æ02). In cirrhotic patients, 24-h urinary recovery of PEGs 1500 and 3350 was significantly higher compared
with healthy controls.
Conclusions Although in our animal model PPIs induced intestinal overgrowth, stage of liver disease rather than
PPI use was the predominant factor determining infection risk in cirrhotic patients. Increased intestinal perme-
ability may be a factor contributing to infection risk.
Keywords Acid-suppressive therapy, bacterial infection, bacterial overgrowth, intestinal permeability, proton
pump inhibitors, spontaneous bacterial peritonitis.
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Introduction
Patients with liver cirrhosis are at increased risk for developing
a broad range of bacterial infections, including spontaneous
bacterial peritonitis (SBP), urinary tract infections, pneumonia,
skin infections and bacteraemia ⁄ sepsis [1–3]. In approximately
30% of cirrhotic patients admitted to the hospital, a bacterial
infection is diagnosed [2,3]. The development of bacterial infec-
tions leads to prolonged hospital stay and increased morbidity
and mortality [2,4,5]. Although the exact mechanism by which
bacterial infections develop in cirrhotic patients is unknown,
increased intestinal permeability may promote bacterial trans-
location and increase infection rate [6–10]. In addition, cirrhotic
patients often exhibit complement deficiency, reticuloendothe-
lial system depression and leucocyte dysfunction [1,11,12].
Acid-suppressive therapy with proton pump inhibitors
(PPIs) or H2 receptor antagonists (H2RAs) could in theory also
contribute to the development of bacterial infections, as their
use is associated with bacterial overgrowth in the small intes-
tine. H2RAs have been found to increase the risk of bacterial
infections (especially pneumonia) in intubated intensive care
patients [13]. Furthermore, a recent meta-analysis found an1These authors contributed equally to this work.
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increased risk of community-acquired pneumonia in adult PPI
users [14]. As far as cirrhotics are concerned, four retrospective
studies on the association between PPI use and risk of SBP in
cirrhotic inpatients with ascites reported contradictory results
[6,15–18]. It remains unknown whether acid-suppressive ther-
apy increases specifically the risk of SBP or risk of bacterial
infections in general in cirrhotic patients.
In this study, we explored in a rat model, potential adverse
effects of 6-week administration of high-dose PPIs on bacterial
overgrowth and evaluated the potential association between
use of acid-suppressive drugs and risk of various bacterial
infections in cirrhotic outpatients. In addition, we assessed
intestinal permeability in this patient group.
Methods
Rat study
Animals and conditions. Thirty-two male Wistar rats (Harlan
CPB, Austerlitz, the Netherlands), weighing approximately
175 g, were housed under standard laboratory conditions. Rats
were randomly allocated to three experimental groups. Rats in
group A (n = 10) received omeprazole (Astra Zeneca, Gothen-
burg, Sweden) in a dose of 400 lg ⁄kg daily by oral gavage,
which is equivalent to 80 mg omeprazole administered to
humans. Two milligram per millilitre of NaHCO3 (Sigma, Stein-
heim, Germany) was added to the omeprazole, and this was
suspended in 0Æ3% hydroxypropyl methylcellulose (Sigma),
adjusted to pH 9Æ0 with NaOH. Rats in group B (n = 12) were
subjected to gastrectomy with oesophagojejunostomy (GEJ) in
order to investigate the effect of total achlorhydria. Twelve rats
were operated based on our previous experience that approxi-
mately 20% of the rats will be lost because of postoperative
complications. Rats in group C (n = 10) served as controls. All
rats were sacrificed after 6 weeks. Throughout the experiment,
animals had access to commercial semisynthetic rat chow
(Hope Farms, Woerden, the Netherlands) and drinking water
ad libitum.
Surgical techniques. Rats in group B were anaesthetized with
a gaseous mixture of 3% isoflurane, 64%N2O and 33% O2.
Gastrectomy was performed through median laparotomy with
the oesophagus attached end-to-site to the jejunum, 3 cm distal
of the ligament of Treitz. Buprenorphin (0Æ05 mg ⁄kg) and
drinking water were administered directly after surgery, and
rat chow was provided ad libitum after 24 h.
Sample collection and analyses of bacterial flora. After
6 weeks, rats were anaesthetized and tissue samples (1 cm in
diameter) were resected from the jejunum (2 cm from the oes-
ophageojejunostomal anastomosis). Samples were immediately
placed on blood agar, MacConkey agar, Brucella blood agar,
Bacteroides bile esculine agar and kanamycin ⁄vancomycine
agar (Becton Dickinson, Alphen a ⁄d Rijn, the Netherlands).
Thereafter, animals were sacrificed by decapitation. The plates
were transferred to a 37C incubator and cultured under aero-
bic (24 and 48 h) and anaerobic (48 and 120 h) conditions. After
incubation, pure cultures were isolated from the cultured bacte-
ria, and these were morphologically analysed using the Vitek
system (bioMe´rieux, Boxtel, the Netherlands) [19].
Prospective cohort study
Patients. Eighty-four consecutive cirrhotic patients from the
outpatient clinics of two academic hospitals in the Netherlands
were followed prospectively for complications in the period
from June 2007 to June 2010. This prospective cohort is primar-
ily aimed to explore relationship between nutritional status and
complication rate [20]. Diagnosis of cirrhosis was established
by a combination of clinical, laboratory, radiological (ultra-
sound, MR, CT, Fibroscan, Echosens, Paris, France) and histo-
logical findings. Determination of the aetiology of cirrhosis was
made using standard diagnostic criteria. For diagnosis of auto-
immune hepatitis, the revised autoimmune hepatitis scoring
system was used [21]. Alcoholic liver disease was diagnosed in
those with regular consumption of at least 60 g ⁄ 7Æ5 units (men)
or 40 g ⁄ 5 units (women) of alcohol daily. Diagnosis of nonalco-
holic steatohepatitis was based on clinical data (obesity, meta-
bolic syndrome), liver histopathology and absence of alcohol
abuse. Cryptogenic cirrhosis was diagnosed when other causes
of cirrhosis had been excluded with appropriate tests. Patients
with hepatocellular carcinoma and pegylated interferon-based
therapy were excluded as these conditions could interfere with
infection risk (n = 15). Although acquired immunodeficiency
syndrome and other serious diseases were additional exclusion
criteria, no patients were excluded for these reasons.
Study design. Patients visited the outpatient clinic at 6-month
intervals, or more frequently if indicated. The occurrence of
SBP and other bacterial infections, including pneumonia and
infection of skin or urinary tract, was registered prospectively.
SBP was defined as granulocyte count >0Æ25 · 109 ⁄L in ascites
with or without positive ascitic fluid bacterial culture [22,23].
Follow-up ended in case of death, liver transplantation or time
of final evaluation (June 1 2010). For the current analysis, charts
of all patients were reviewed to investigate whether patients
were on acid-suppressive therapy during any period of follow-
up. Start and end date, dosage, treatment duration and indica-
tion for use of acid-suppressive therapy were recorded for all
patients. Gastro-oesophageal reflux disease (GERD), peptic ulcer
disease and gastroprotection in case of nonsteroidal anti-inflam-
matory drugs (NSAIDs) use were considered valid indications.
European Journal of Clinical Investigation Vol 42 761
BACTERIAL INFECTIONS IN CIRRHOSIS: ROLE OF PROTON PUMP INHIBITORS
Intestinal permeability
Patients. Intestinal permeability was evaluated in 12 cirrhotic
patients and nine healthy individuals. Subjects with gastroin-
testinal complaints, renal insufficiency and any co-morbidity
other than liver cirrhosis were excluded, and subjects were not
allowed to use lactulose, NSAIDs, aspirin or alcohol during
2 weeks prior to the test.
Study design. After an overnight fast, a solution containing
5 g polyethylene glycol (PEG) 400, 5 g PEG 1500 (Bufa Chemi-
cal Company, Uitgeest, the Netherlands) and 40 g PEG 3350
(Sigma Chemical Company, St. Louis, MO, USA) dissolved in
100 mL water was orally administered [24–27]. After ingestion,
subjects fasted during another 6 h and collected urine during a
24-h period in two containers (container I: first 8 h, container II:
hours 9–24). Urine samples were stored at )20 C until further
analysis by reversed-phase high-performance liquid chroma-
tography as described before [28,29].
These studies were approved by the Medical Ethical Com-
mittee for humans as well as the Animal Experiments Commit-
tee under the National Experiments on Animals Act and
adhered to the rules laid down in the national law that serves
the implementation of ‘Guidelines on the protection of experi-
mental animals’ by the Council of Europe (1986), Directive
86 ⁄ 609 ⁄EC. From human subjects, written informed consent
was obtained.
Statistical analysis
SPSS for Windows, version 15.0.1 (SPSS Inc., Chicago, IL, USA),
was used for statistical analysis. Values are expressed as
means ± SD for data with Gaussian distribution; otherwise
medians with range are used. Proportions were compared
using the Pearson chi-square test or Fisher’s exact test, where
appropriate. Continuous variables were compared using the
Student’s t-test or Mann–Whitney U test, where appropriate.
Kaplan–Meier survival analysis with log-rank test was used to
compare bacterial infection rates between patients with and
without PPI. Cases without bacterial infection were censored at
time of liver transplantation, death or end of follow-up.
Multivariate Cox regression analysis was used to identify inde-
pendent predictors for development of bacterial infection.
Atwo-sidedP-value<0Æ05wasconsideredstatisticallysignificant.
Results
Rat study
All rats in group A (PPI) and C (nontreated) completed the
study. Two of 12 rats (17%) treated with GEJ (group B) died
before the endpoint of the study because of anastomotic dehis-
cence (day 4) or stricture at the GEJ anastomosis (day 28). These
animals are not included in the analysis. Anaerobic bacterial
overgrowth could not be assessed in one PPI-treated rat
because of complete overgrowth of the plates by a highly motile
swarming Proteus mirablis strain.
Bacterial characterization of bacterial flora. Presence of
anaerobic bacteria was more common in jejunum of PPI-treated
and GEJ-treated rats compared with controls (Table 1). Clostrid-
ium perfringens was demonstrated in the jejunum of all GEJ-
treated rats and 4 ⁄ 9 PPI-treated rats (44%) and none of the
nontreated rats. Bacteroides species were found in 4 GEJ-trea-
ted rats (40%), 4 PPI-treated rats (44%) and none of the non-
treated rats. A variety of other facultative aerobic bacteria
species was also present in the jejunum of PPI-treated and GEJ-
treated rats (Table 1).
Prospective cohort study
Baseline characteristics of the 84 cirrhotic outpatients are given
in Table 2.
Use of acid-suppressive drugs. Fifty-two patients (62%) used
an acid-suppressive agent during the study period (pantopraz-
ole or omeprazole in 51 patients, ranitidine in one patient). The
vast majority of patients who used acid-suppressive drugs was
on a once-daily dosing regimen (42 patients, 82%) and used a
daily dose of 40 mg (44 patients, 86%). None of the patients
used their drugs on an ‘as needed basis’. Median duration of
acid-suppressive therapy was 30 months (IQR 11–51 months).
In 43 patients (83%), no indication for PPI use was documented.
In patients with a documented indication, GERD was the most
Table 1 Bacteria found in the jejunum of rats treated with a
proton pump inhibitor (PPI), gastrectomy plus
oesophagojejunostomy (GEJ) or not treated (controls)
Bacterial species
Group A
PPI,%
Group B
GEJ,%
Group C
Controls,% P-value
Clostridium
perfringens
44 100 0 <0.01
Bacteroides spp. 44 40 0 0Æ05
Escherichia coli 100 50 0 <0.01
Staphyloccus aureus 33 40 0 0Æ08
Morganella morganii 11 40 0 0Æ05
Streptococcus spp. 78 30 10 0Æ01
Lactobacillus spp. 11 0 30 0Æ14
Enterococcus
faecalis
78 40 0 <0.01
Proteus mirabilis 33 10 0 0Æ10
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common diagnosis (n = 5, 10%), followed by peptic ulcer dis-
ease (n = 2, 4%), gastric protection in case of NSAID use (n = 1,
2%) or a combination of these indications (n = 1, 2%).
Bacterial infections during follow-up. After a median follow-
up of 28 months (IQR 15–31 months), 16 patients died (19%),
because of end-stage liver disease (n = 10), hepatocellular carci-
noma (n = 2) or an unknown cause (n = 4). Seventeen patients
(20%) underwent liver transplantation, whereas the remaining
51 patients (61%) survived without liver transplantation or
were on the waiting list for transplantation at end of follow-up.
A total of 102 hospitalizations occurred in the total cohort of 84
patients, with 33 patients (39%) without admission, 27 patients
(32%) being admitted once during follow-up and 24 patients
(29%) with ‡2 admissions. The number of patients admitted at
least once during follow-up was significantly higher in PPI
users compared with patients who did not use a PPI: 75% vs.
38% (P = 0Æ001).
A total of 24 patients (29%) experienced a bacterial infection,
requiring treatment with antibiotics. Infection was community
acquired in 19 patients (79%) and hospital acquired in 5
patients (21%). Median duration of follow-up at the time of
infection was 6 months (IQR 2–21 months). SBP was diagnosed
in nine patients (11%), pneumonia and urinary tract infection
both in three patients (4%), erysipelas and bacterial gastrointes-
tinal infection both in two patients (2%), meningitis in one
patient (1%), diabetic foot infection in one patient (1%) and
sepsis of unknown origin in three patients (4%). Seven patients
(29%) with a bacterial infection died within 1 month after diag-
nosis (SBP, n = 4; urinary tract infection, n = 2; sepsis of
unknown origin, n = 1). Compared with the patients who did
not develop a bacterial infection during follow-up, patients
with a bacterial infection were older (mean age 60 years vs.
53 years, P = 0Æ01) and had more advanced liver disease, as
expressed by a higher Child-Pugh class (62% vs. 33% Child-
Pugh B ⁄C, P = 0Æ02), lower serum albumin concentration (mean
33Æ2 g ⁄L vs. 36Æ3 g ⁄L, P = 0Æ05) and prolonged prothrombin
time (median 16Æ7 s vs. 14Æ5 s, P < 0Æ001) (Table 3). Of note,
follow-up time was significantly shorter in patients with a bac-
terial infection (median 16 vs. 29 months, P = 0Æ01) (Table 3).
Seventeen patients (71%) who developed a bacterial infection
during follow-up used a PPI at the time of infection, compared
with 34 patients (57%) in the noninfection group (P = 0Æ23).
There were no differences in doses of acid-suppressive drugs
between patients with infection and those without infection.
Median duration of PPI use at the time of infection was
16 months (IQR 2–44 months). In univariate survival analysis,
patients who used a PPI tended to develop an infection more
frequently than patients without a PPI (Fig. 1, log-rank test,
P = 0Æ11). In multivariate Cox regression analysis, PPI use was
not an independent predictor of bacterial infection (HR 1Æ2,
95% CI 0Æ5–3Æ0, P = 0Æ72) after correction for Child-Pugh class
(HR 3Æ6, 95% CI 1Æ5–8Æ7, P = 0Æ004) and age (HR 1Æ05, 95% CI
1Æ01–1Æ09, P = 0Æ02). We also conducted the analysis with only
SBP as outcome and obtained similar results: in multivariate
analysis, Child-Pugh class B ⁄C was an independent predictor
of SBP (HR 6Æ1, 95% CI 1Æ2–30Æ7, P = 0Æ03), whereas PPI use was
not (HR 1Æ8, 95% CI 0Æ4–9Æ1, P = 0Æ46).
Seventeen patients (20%) died during follow-up, of whom
82% used a PPI compared with 57% in patients still alive at the
end of follow-up. In univariate survival analysis, mortality was
higher among patients who used a PPI compared with those
who did not use a PPI (log-rank test P = 0Æ01). However, PPI
use was not significantly associated with mortality (HR 3Æ2,
95%CI 0Æ9–11Æ9, P = 0Æ09) after correction for Child-Pugh class
B ⁄C (HR 7Æ5, 95% CI 2Æ3–24Æ5, P = 0Æ001).
Table 2 Baseline characteristics of 84 cirrhotic patients in
prospective cohort study
Characteristic
Age (years) 55 ± 12
Male gender (n) 56 (67%)
Body weight (kg) 78 ± 19
Aetiology cirrhosis (n)
Viral hepatitis 26 (31%)
Alcohol 21 (25%)
PSC ⁄PBC 15 (18%)
Autoimmune hepatitis 9 (11%)
Other 13 (15%)
Child-Pugh class (n)
A 49 (58%)
B 29 (35%)
C 6 (7%)
Ascites (n) 29 (35%)
MELD score 10 (6–27)
On waiting list transplantation (n) 20 (24%)
Diabetes mellitus (n) 18 (21%)
Creatinine (lM) 81 (43–247)
Bilirubin (lM) 24 (3–845)
Prothrombin time (s) 15Æ1 (12Æ4–25Æ5)
Platelets (·109 ⁄ L) 116 (9–477)
Serum albumin (g ⁄ L) 35Æ4 ± 6Æ5
Data represent mean ± SD or median (range). MELD, model for end-stage
liver disease.
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Intestinal permeability
Polyethylene glycol solution was administered to 12 cirrhotic
patients and nine healthy subjects. All subjects had normal
renal function. In cirrhotic patients, the underlying cause of
cirrhosis was viral hepatitis in 42%, alcohol in 33% and other
in 25% of patients. Nine patients had Child-Pugh A liver dis-
ease (75%) and three patients had Child-Pugh B liver disease
(25%). Of the 12 cirrhotic patients, 5 patients (42%) used a PPI
compared with none of the control patients.
Figure 2 shows the recoveries of the various PEGs in cirrhotic
patients and healthy controls. PEGs 400, 1500 and 3350 were
largely excreted within the first 8 h after the administration of
PEG solution (Fig. 2b,d,f), with the exception of PEG 3350 in
cirrhotic patients (Fig. 2f). No significant differences in 24-h
recoveries of PEG 400 were observed between cirrhotic patients
[median 31% (IQR 28–39)] and healthy controls [29% (25–30),
P = 0Æ16] (Fig. 2a). In contrast, 24-h recoveries of PEG 1500
[2Æ1% (1Æ5–4Æ2) vs. 1Æ3% (0Æ9–1Æ7), P = 0Æ02, Fig. 2c] and PEG
3350 (0Æ19% (0Æ13–0Æ28) vs. 0Æ11% (0Æ09–0Æ18), P = 0Æ02, Fig. 2e)
were significantly higher in cirrhotic patients compared with
healthy controls. No significant differences in intestinal perme-
ability between cirrhotic PPI users and cirrhotic patients who
did not use a PPI were found (data not shown).
Discussion
In this study, we explored a possible association between PPI
use and occurrence of bacterial infections in cirrhotic outpa-
tients as well as potential contributing mechanisms. Our experi-
mental animal data indicated bacterial overgrowth in rats
treated with PPI, comparable to rats that underwent GEJ.
Bacterial infection rate in our cohort of consecutive cirrhotic
outpatients was high, but was not found to be related to PPI
use. In contrast, state of liver disease was the most important
factor in the development of bacterial infections, with
Child-Pugh B or C patients having a threefold increased risk of
bacterial infection compared with Child-Pugh A patients.
Furthermore, increasing age was an independent predictor of
bacterial infections. We also conducted the analysis with only
SBP as outcome and obtained similar results.
Previous reports on PPI use and infection risk in cirrhotic
patients focused on SBP only and – except for one study – only
included hospitalized patients with ascites [6,15–18]. In a
retrospective matched case–control study among 140 cirrhotic
inpatients with ascites, prehospital PPI use and low ascitic fluid
protein content were independent predictors of SBP [15]. In line
with these results, in a recent retrospective review of 176
cirrhotic inpatients, PPI use was found to be an independent
risk factor for the development of SBP besides Child–Pugh class
C and high model for end-stage liver disease (MELD) scores
[17]. In contrast, a retrospective cohort study in 116 consecutive
cirrhotic patients with ascites who underwent diagnostic para-
centesis upon hospital admission did not find an association
between PPI use and development of SBP [16]. Furthermore, in
Table 3 Characteristics of cirrhotic patients who did vs. did not
develop bacterial infection
Characteristic
Infection
n = 24
No infection
n = 60 P-value
Age (years) 60 ± 11 53 ± 12 0Æ01
Male gender (n) 17 (71%) 39 (65%) 0Æ61
Body weight (kg) 76 ± 26 79 ± 15 0Æ62
Child-Pugh class (n)
A 9 (38%) 40 (67%) 0Æ02
B 11 (46%) 18 (30%)
C 4 (16%) 2 (3%)
On waiting list
transplantation (n)
7 (29%) 13 (22%) 0Æ47
MELD score 13 (6–27) 10 (6–16) <0Æ01
Diabetes mellitus (n) 8 (33%) 10 (17%) 0Æ09
PPI use (n) 17 (71%) 34 (57%) 0Æ23
Follow-up duration
(months)
16 (0Æ5–31) 29 (0Æ5–36) 0Æ01
Prophylaxis SBP (n)† 2 (8%) 7 (12%) 0Æ66
Creatinine (lM) 93 (43–247) 81 (53–172) 0Æ35
Previous SBP (n) 4 (17%) 4 (7%) 0Æ22
Data represent mean ± SD or median (range). MELD, model for end-stage
liver disease.
SBP, spontaneous bacterial peritonitis.
†Norfloxacin 400 mg once daily.
Figure 1 Kaplan–Meier curve comparing bacterial infection
rate in 84 cirrhotic patients with vs. without use of PPI (log-rank
test P = 0.11). Vertical lines represent bacterial infection, and
patients without infection are censored at the time of liver
transplantation, death or end of follow-up.
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the only other available study in cirrhotic outpatients, no signif-
icant association between use of acid-suppressive therapy and
occurrence of SBP was found [6]. Differences between various
studies may relate to different patient characteristics. For exam-
ple, a priori chance of infection or SBP is much higher in admit-
ted patients with persistent ascites compared with outpatients.
Furthermore, frequency of PPI use varied greatly between these
studies [6,15–17].
Of importance, in our study, PPIs were often prescribed in
cirrhotic patients without an accepted indication. Although
PPIs are generally regarded to be drugs with a good safety pro-
file, previous reports in noncirrhotic patients indicate that PPI
use is associated with an increased risk of community-acquired
pneumonia [14], as well as Clostridium difficile infection and
other enteric infections [30]. Therefore, routine use of acid-sup-
pressive drugs in cirrhotic patients is not recommended in the
absence of an appropriate indication. Clinicians should
constantly re-evaluate the use of PPIs in both cirrhotic inpatient
and outpatients.
An alternative explanation for the high infection rate in
cirrhotic patients could be increased intestinal permeability.
In line with this hypothesis, we found intestinal permeability
to be increased in cirrhotic patients compared with healthy
controls, in line with earlier reports [9,10]. We used PEGs of
different molecular masses which allow assessment of
size-dependent intestinal permeability [24,25]. In contrast to
(a) (b)
(c) (d)
(e) (f)
Figure 2 Cumulative 0- to 24-h recoveries of polyethylene glycols with molecular mass 400 (a), 1500 (c) and 3350 (e) as well as
relative 0- to 8-h and 8- to 24-h recoveries of the same molecules (b, d and f) in cirrhotics patients compared with healthy controls.
Each symbol represents one subject, with circles indicating Child-Pugh A cirrhotics, squares Child-Pugh B cirrhotics and triangles
healthy controls. The horizontal line indicates the median value for cirrhotics and healthy controls. Only P-values <0.05 are shown.
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previously used permeability tests as 51Cr–EDTA and sugar
absorption tests, the PEG solution contains relatively large
compounds (PEG 3350) that mimic the structure of bacterial
endotoxins as lipopolysaccharide [24,25]. One might speculate
that PPI use among cirrhotic patients might have influenced
our results. However, we did not find a significant difference
in intestinal permeability between cirrhotic patients with and
without PPI.
Aetiology of bacterial infections in cirrhotic patients is proba-
bly multifactorial. It is known that intestinal permeability, gut
flora and motility are altered in cirrhotic patients [31–34].
Furthermore, several abnormalities in immune response have
been described in cirrhotic patients [11,12]. As these risk factors
already exist in cirrhotic patients not on PPI therapy, use of PPIs
might not have a significant additional effect on infection risk.
In conclusion, although in our animal model PPIs induced
intestinal overgrowth, stage of liver disease rather than PPI use
was the predominant factor determining infection risk in
cirrhotic patients. Increased intestinal permeability may be a
factor contributing to infection risk.
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